IP Library Granted Patent US 7,858,757
Granted Patent B2
US 7,858,757 · App. 10/599,512 · Granted Dec 28, 2010

Monoclonal antibodies with specificity for fetal erythroid cells

Assignee: Adnagen AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,858,757
App. No.
10/599,512
Granted
Dec 28, 2010
Kind
B2
Abstract

The present invention concerns a monoclonal antibody and corresponding hybridoma cells and antigens suitable for isolating fetal cells from maternal blood. The monoclonal antibody reacts with a surface antigen present on fetal red blood cells including their nucleated precursor cells, but not with surface antigens on adult erythroid cell.

Claims (7)

1. A monoclonal antibody reacting with a surface antigen present on fetal red blood cells and their nucleated precursor cells, but not with CD71 or other surface antigens on adult erythroid cells.

2. The antibody according to claim 1 , having reactivity with fetal erythroid cells and their nucleated precursor cells, which express the CD71 antigen but are negative for CD45 antigen expression.

3. A hybridoma cell producing a monoclonal antibody reacting with a surface antigen present on fetal red blood cells and their nucleated precursor cells, but not with CD71 or other surface antigens on adult erythroid cells.

4. A method for detection or identification of fetal red blood cells in a sample comprising labeling said fetal red blood cells and their nucleated precursor cells with a monoclonal antibody according to claim 1 .

5. The method according to claim 4 , wherein the sample is maternal blood.

6. The method according to claim 4 , where said fetal red blood cells and their nucleated precursor cells are, subsequent to the detection and identification, further analyzed for a chromosomal or genetic defects.

7. The method according to claim 4 , further comprising separating fetal red blood cells and their nucleated precursor cells binding the monoclonal antibody by flow cytometry, solid phase separation, immunomagnetic bead separation, or panning on plastic surfaces.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2015
From: ALERE DIAGNOSTICS GMBH
To: KELLBENX INC.
Reel/Frame 035709/0772 →
CHANGE OF NAME Recorded May 26, 2015
From: ADNAGEN GMBH
To: ALERE DIAGNOSTICS GMBH
Reel/Frame 035771/0395 →
CHANGE OF NAME Recorded Dec 17, 2012
From: ADNAGEN AG
To: ADNAGEN GMBH
Reel/Frame 029485/0927 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SECOND INVENTOR'S NAME FROM 'WILFRIED ALBERT' TO --WINFRIED ALBERT--. PREVIOUSLY RECORDED ON REEL 019349 FRAME 0928. ASSIGNOR(S) HEREBY CONFIRMS THE ENTIRE RIGHT, TITLE AND INTEREST FOR THE APPLICATION FOR UNITED STATES LETTERS PATENT, SERIAL NO. 10/599,512. Recorded Aug 23, 2007
From: HOLLMANN, CHRISTIANE; ALBERT, WINFRIED; ZIMMERMANN, SILKE; STACHELHAUS, STEFAN
To: ADNAGEN AG
Reel/Frame 019736/0010 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2007
From: HOLLMANN, CHRISTIANE; ALBERT, WILFRIED; ZIMMERMANN, SILKE; STACHELHAUS, STEFAN
To: ADNAGEN AG
Reel/Frame 019349/0928 →
Priority Claims (1)
EP 04007811 · Mar 31, 2004 · regional
Continuity (1)
Related Publication 20070275418A1 · Nov 29, 2007